Drugs / Ansuvimab
Ansuvimab
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03478891 | May 2018 → Mar 2019 | — | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04822376 | Oct 2021 → Apr 2022 | Ebola hemorrhagic fever | ANRS, Emerging Infectious Diseases | Unknown | No outcome recorded |
| Phase 2/31 trial · 1 met primary | ||||||
| Phase 2/3 | NCT03719586 | Nov 2018 → Sep 2019 | Ebola hemorrhagic fever | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | Met primary |
| Phase not stated1 trial | ||||||
| — | NCT05067166 | — | Ebola hemorrhagic fever | Ridgeback Biotherapeutics, LP | Available | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2019-11-27 | Regeneron Pharmaceuticals | Results New England Journal of Medicine Publishes Results of Ebola Clinical Trial Confirming Superiority of Regeneron's REGN-EB3 to ZMapp in Preventing Ebola Deaths regeneron.com ↗
Although a second investigational treatment, mAb114, did not meet this statistical threshold, it had notable activity, and the decision was made for these two strongest-performing investigational therapies to continue to be administered to patients in a trial extension phase. |
All press releases naming this drug 5 releases
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ansuvimab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05067166 ↗ |
| Known as | Ansuvimab zykl | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594388 ↗ |
| Known as | Ebanga | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594388 ↗ |
| Known as | EboV mAb114 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594388 ↗ |
| Known as | EVB-114 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594388 ↗ |
| Known as | MAb114 | “VRC-EBOMAB092-00-AB (MAb114) is a human immunoglobulin (IgG1) monoclonal antibody (MAb) targeted to the Zaire ebolavirus (EBOV) glycoprotein (GP).” NCT03478891 ↗ |
| Known as | VRC-EBOMAB092-00-AB | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03478891 ↗ |
| Modality | Monoclonal antibody | “VRC-EBOMAB092-00-AB (MAb114) is a human immunoglobulin (IgG1) monoclonal antibody (MAb) targeted to the Zaire ebolavirus (EBOV) glycoprotein (GP).” NCT03478891 ↗ |
| Route | Intravenous | “The drug was given to participants intravenously over 30 min” PMID 30686586 ↗ Jan 2019 |